because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
Current evidence underscores the necessity of further scientific assessment, more precise regulatory definitions, and robust banned-substance detection strategies to ensure safe use among athletes, tactical professionals, and the general public
No personalized use recommendation outputs
Reason 4: pH can shift Freezing can alter the pH of the solution and throw off dissolved gas balance
Regarding lactation, limited data are available on tirzepatide use during breastfeeding